Gsa Capital Partners LLP Dynavax Technologies Corp Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$11.7 - $14.98 $148,882 - $190,620	12,725 New	12,725 $157,000
Q4 2022 Feb 13, 2023	BUY	$10.27 - $13.29 $201,435 - $260,670	19,614 Added 49.58%	59,173 $630,000
Q3 2022 Nov 14, 2022	BUY	$9.93 - $17.44 $392,820 - $689,908	39,559 New	39,559 $413,000
Q2 2020 Aug 11, 2020	SELL	$2.94 - $9.1 $173,621 - $537,400	-59,055 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$2.27 - $6.2 $134,054 - $366,141	59,055 New	59,055 $208,000
Q3 2019 Nov 12, 2019	SELL	$2.69 - $4.85 $39,556 - $71,319	-14,705 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$3.65 - $7.89 $53,673 - $116,022	14,705 New	14,705 $59,000

273

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.6B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.